Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 220 participants.

Also called NCT04075981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04075981
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04075981. Randomized; triple masking; primary purpose treatment. Start 2019-09-30 (actual); primary completion 2025-10-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
Acronym
BOTAF
Condition
Cardiac Surgery
Intervention (Drug)
Botulinum Toxin Type A Injection [Xeomin]
Intervention (Other)
Drug placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Merz Pharmaceuticals (class: industry)
Collaborator
Ministry of Health, France (class: other government)

Record details

Record id
cardio:ct-nct04075981
Content hash
bb8c495249ddc6c0a69903bc0ecedadf2637b4eb274f2523c0a2e95d2af2cba1